United Kingdom studies offering anti-obesity drug to unemployed

A medicine against obesity and diabetes

the drug in question is tirzepatideMarketed in the country as Mounjaroand company assets Eli Lilly. It is the responsibility of the known OzempicAnother drug, owned by Novo Nordisk, was originally intended to fight diabetes, but its use for weight loss has become widespread. It so happened that according to Reuters, Eli Lilly has recently announced an investment of 279 million pounds in the United Kingdom.

The NHS already prescribes some of these medicines for patients with obesity or diabetes.

Health Minister, Wes Streetinghas given this assurance Obesity costs the NHS £11 billion a year (over 13,000 million euros) and means that patients are on longer sick leave or even have to leave the labor market.

“The long-term benefits of these drugs could be huge,” the minister said in an article published in the newspaper. Wire“For many people, these weight loss injections will change their lives, This will help them get back to work and reduce demands on the NHS,

However, patients will also have to change their lifestyle habits, Streeting warned. “The NHS cannot always be expected to fix unhealthy lifestyles.”

studied at manchester university

The minister has put forward a proposal “Large randomized study on the effectiveness of tirazeptide”.The University of Manchester will co-ordinate the study, which will include 3,000 peopleand will collect data on your health status, your employment status and your medical leave.

Earlier this month, NHS England set out a plan to provide the drug to almost a quarter million patients within three years.

NHS chief Amanda Pritchard said, “Obesity is one of the biggest public health problems we face and we know weight loss medicines will be a game-changer.”